ecancermedicalscience

Short Communication

WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results

3 Dec 2015
Felipe Ades, Nise Yamaguchi

In recent years, with the rise of immunotherapeutic agents for cancer treatment, we have observed a paradigm shift in oncology drug development. One common problem accompanying such paradigm shifts is how to build research strategies to fit the mechanism of action of the newer compounds. Developing immunotherapy in oncology requires us to address the unique characteristics of immunotherapeutic agents and to provide adequate tools for their evaluation, including the adjustment of clinical trial endpoints. Immunotherapy creates patterns of response different from those of chemotherapy, and thus they are not captured by the traditional World Health Organisation (WHO) tumour response criteria or the RECIST. Revisiting the results of pembrolizumab in patients with melanoma can help to evaluate the efficacy of the immune-related response criteria (irRC) as the gold standard for evaluating the clinical response of immunologic agents in oncology.

Related Articles

Miguel Araujo-Meléndez, Mirza Jacqueline Alcalde-Castro, Andrea De-la-O-Murillo, Thierry Hernandez-Gilsoul, Enrique Soto-Perez-de-Celis, Roberto Gonzalez-Salazar, Yanin Chavarri-Guerra
Camilla Engelsmann, Gitte Wooler, Vladimira Horvat, Shailesh Balasaheb Kolekar
Carmen Saiz, Angel Montero, Mercedes López, Bruno Zambrana, Beatriz Alvarez, Jeannette Valero, Raquel Ciervide, Ovidio Hernando, Mariola Garcia-Aranda, Emilio Sanchez, Leyre Alonso, Xin Chen-Zhao, Rosa Alonso, Carmen Rubio
Sasongko Hadi Priyono, Winardi Budiwinata, Budianto Tedjowitono, Effendy, Muhamad Daffa Ibnurasy Pratama
Sidhart Misra, Zainab Yusufali Motiwala, Ayyaz Mulla, Jagatheswaran Chinnathambi, Danny Darlington Carbin